Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA
Expanding Opportunities in Asia
SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage
company aimed at developing targeted peptide therapies for hard to treat cancers,
announced that its Chief Executive Officer, Chris Adams, will present at the Chinese
Biopharmaceutical Association (CBA) USA conference. The CBA conference will take
place on June 9, 2018 in Gaithersburg, MD.
“The CBA conference offers Andarix the opportunity to present its findings and share its
clinical message on a global stage in front of audience with extensive connections in the
Chinese market”, say Chris Adams, CEO of Andarix
About Tozaride
Tozaride is a novel, best-in-class therapeutic for lung and other cancers, which is based
on a radio-labeled somatostatin peptide. Early clinical studies demonstrated that
Tozaride is well tolerated and that treatment can promote disease stabilization and
improve overall survival in heavily pre-treated advanced lung cancer patients. Tozaride
targeted radiotherapy represents a new treatment paradigm which is expected to yield
significant clinical benefits for both small cell lung cancer (SCLC), and non-small cell
lung cancer (NSCLC) patients. This therapeutic stands to provide an additional
treatment option for patients who are not eligible for, or who have not responded to
current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company aimed at developing targeted
imaging and therapeutics for lung, neuroendocrine, and other cancers based on a
proprietary somatostatin peptide conjugate. Extensive research has demonstrated that
somatostatin receptors are highly up-regulated in several solid tumors, and lung cancers
in particular, thus supporting the efficacy of somatostatin conjugates as targeted
therapeutics for these cancers. Lung cancer is the second most common cancer in both
men and women in the US and is the leading cause of cancer mortality. In 2013, there
were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with
42,000 small cell lung cancer patients. To learn more about Andarix, please visit
www.andarix.com .
About CBA
CBA’s primary mission is to bridge the biopharmaceutics gap between US and China.
Headquartered in Maryland, CBA currently has more than 700 active members, over
3000 registered individual members, and more than 60 institutional members. Most CBA
members belong to local biopharmaceutical companies, universities, research
institutions, and government agencies. In addition to US members, CBA also has
members residing in China, Europe, Canada, Australia, Singapore, and Japan.
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com